Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | OGG1 | O15527 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814001 | 0.78 | HSP90AB1 (0.44) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL20562211 | 0.77 | ALDH1A1 (0.42) | GPR35ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL2428809 | 0.77 | HSP90AB1 (0.39) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL2912487 | 0.77 | HPGD (0.41) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12678947 | 0.77 | HSP90AB1 (0.41) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL13751380 | 0.77 | HPGD (0.45) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL15055959 | 0.75 | HPGD (0.49) | ALDH1A1MAPTGAAMEN1KMT2A | |
| SCHEMBL27618386 | 0.74 | GPR35 (0.41) | GPR35ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL5485173 | 0.74 | PDGFRB (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL31701357 | 0.74 | PDGFRB (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-7358253-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-7235555-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-06-26 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | GPR35 1348/4885PDGFRB 3436/4885FGFR1 1738/4885 |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | GPR35 1588/4885PDGFRB 3597/4885FGFR1 3625/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | GPR35 1348/4885PDGFRB 3436/4885FGFR1 1738/4885 |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | MYLK2, LCK, DGKK | GPR35 1001/4885PDGFRB 3644/4885FGFR1 2136/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | GPR35 698/4885PDGFRB 3534/4885FGFR1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.